Zhangzhou Pientzehuang Pharmaceutical., Ltd
600436
株式のランク
#1903
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. is a Chinese company,... Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. is a Chinese company, headquartered in Zhangzhou, that specializes in the production and distribution of traditional Chinese medicines. Its offerings, predominantly sold under the renowned Pien Tze Huang brand, reach consumers both domestically within China and across international markets. Beyond its core pharmaceutical products, the company's expansive portfolio encompasses health and wellness items, beauty care products, household chemical goods, a variety of medical devices, and nutritional supplements. The firm operates as a subsidiary of Zhangzhou Jiulongjiang Group Co., Ltd.
株価
$18.20
時価総額
$10.98B
変化（1日）
-0.71%
変化（1年）
-28.52%
国
CN
取引 Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436)
カテゴリー
Healthcare
Zhangzhou Pientzehuang Pharmaceutical., Ltd（600436）の利益
2026 時点の利益 TTM: 0
Zhangzhou Pientzehuang Pharmaceutical., Ltd の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Zhangzhou Pientzehuang Pharmaceutical., Ltd の利益の推移（2001 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2025 | $362.73M | -25.18% |
| 2024 | $484.82M | 1.87% |
| 2023 | $475.93M | 10.25% |
| 2022 | $431.69M | -4.37% |
| 2021 | $451.39M | 49.01% |
| 2020 | $302.92M | 28.26% |
| 2019 | $236.18M | 22.38% |
| 2018 | $192.99M | 33.36% |
| 2017 | $144.72M | 64.93% |
| 2016 | $87.75M | 3.66% |
| 2015 | $84.65M | 1.30% |
| 2014 | $83.57M | -0.52% |
| 2013 | $84.00M | 26.14% |
| 2012 | $66.59M | 37.70% |
| 2011 | $48.36M | 37.40% |
| 2010 | $35.20M | 56.86% |
| 2009 | $22.44M | -9.04% |
| 2008 | $24.67M | 21.55% |
| 2007 | $20.30M | 25.11% |
| 2006 | $16.22M | -1.92% |
| 2005 | $16.54M | 74.86% |
| 2004 | $9.46M | -13.67% |
| 2003 | $10.96M | 2.15% |
| 2002 | $10.73M | 10.14% |
| 2001 | $9.74M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $33.60B | - |
US
|
|
| $17.74B | - |
US
|
|
| $8.70B | - |
US
|
|
| $5.95B | - |
US
|
|
| $21.39B | - |
CH
|
